By According to a study from Riyadh, Saudi Arabia, "Hepatic steatosis in hepatitis C virus (HCV)-infected patients has been shown to enhance the progression of liver fibrosis and decrease the response to antiviral therapy. We aimed to determine the role of HCV genotype 4 (HCV-G4) in the prevalence of hepatic steatosis, its impact on antiviral therapy, and its associations and predictive factors in comparison to HCV-G1-infected patients."
"Treatment-na Chronic Hepatitis C Virus).
The researchers concluded: "The grade of steatosis correlates with GGT, platelet count, and BMI, while the NAS score of steatosis correlates with response to antiviral therapy."
Alqaraawi and colleagues published their study in Digestive Diseases and Sciences (Prevalence and Impact of Hepatic Steatosis on the Response to Antiviral Therapy in Saudi Patients with Genotypes 1 and 4 Chronic Hepatitis C. Digestive Diseases and Sciences, 2011;56(4):1222-1228).
For more information, contact A.A. Abdo, King Saud University, College Medical, Dept. of Medical, POB 2925 59, Riyadh 11461, SAUDI ARABIA.
Publisher contact information for the journal Digestive Diseases and Sciences is: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.
Keywords: City:Riyadh, Country:Saudi Arabia, Region:Asia, Chronic Hepatitis C Virus, Digestive System Diseases, Flaviviridae Infections, Gastroenterology, HCV, Hepatitis Viruses, Hepatology, Human Hepatitis, Infectious Disease, Liver Diseases, RNA Viruses, Viral, Virology
This article was prepared by Hepatitis Weekly editors from staff and other reports. Copyright 2011, Hepatitis Weekly via NewsRx.com.
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com/ .
China's Hepatitis B Virus Market Will Grow To Nearly $900 Million In 2015
14 June 2011
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the hepatitis B virus (HBV) market in China will grow from $601 million in 2010 to nearly $900 million in 2015...
Nosebleeds and Hepatitis C
Capable of transmitting the Hepatitis C virus, exposing other people to infected blood can be a source of great anxiety for individuals with this infectious disease. For those who do not participate in high risk activities - like sharing intravenous drug equipment - there are few times when exposure to blood occurs. That is unless you consider nosebleeds, an event with the capability of exposing anyone in your near vicinity to infected blood..
Pharmaceutical-Online Clinical Trials?
American Journal of Public Health
US Medicaid drug lists cost more, deliver less
The US Medicaid program is likely paying far more than necessary for medications and not offering patients the most effective ones available, by ignoring international evidence-based lists of safe and effective medications, according to a new study by researchers at University of California, San Francisco.
New On The Blog
Hepatocellular carcinoma (HCC);A common cancer
Axium is pleased to add VictrelisTM and IncivekTM ...
Life expectancy slips for females in some parts of...
NY-Pain Clinic Visitors May Have Received Hepatiti...
The Hepatitis C Self-management Programme
Sitges IV Advances the Discussion of Early Access ...
Starting New Hepatitis C Therapies: What Patients ...